Sequential treatment method for p53-deficient cancer
Patent Information
- Application Number
- HK62026124849
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-02
- Filing Date
- 2026-06-15
- Publication Date
- 2026-09-25
- Estimated Expiration
- 2044-07-31
Smart Images
Figure 00000010_0000 
Figure 00000011_0000 
Figure 00000013_0000
Abstract
Description
Abstract This invention discloses a method for treating or alleviating cancer symptoms in a subject, comprising sequentially administering a combination of a thymidine analog and a PARP inhibitor, followed by administration of a G2 kinase inhibitor.
Claims
What is claimed is:
1. A method of treating or alleviating a symptom of a cancer in a subject, the method comprising sequentially administering to the individual a combination of a thymidine analogue and a PARP inhibitor, followed by administration of a G2 -kinase inhibiting drug.
2. The method of claim 1, wherein the G2-kinase inhibiting drug is administered to the subject one, two, three, or four days after the combination of thymidine analogue and PARP inhibitor is administered to the subject.
3. The method of claim 2, wherein the cancer is colorectal cancer, colon cancer, cervical cancer, or pancreatic cancer.
4. The method of claim 3, wherein the symptom of the cancer is a solid tumor.
5. The method of claim 4, wherein the solid tumor comprises a mutated p53 gene.
6. The method of claim 5, wherein the thymidine analogue is comprised by TAS102.
7. The method of claim 5, wherein the G2 -kinase inhibiting drug is a WEE1 inhibitor.
8. The method of claim 7, wherein the WEE1 inhibitor comprises MK1775.
9. The method of claim 5, wherein the PARP inhibitor is Talazoparib.
10. The method of claim 1, wherein the thymidine analogue is comprised by TAS 102, thePARP inhibitor is Talazoparib, and the G2-kinase inhibiting drug is MK1775.